Identification of biomarkers of disease heterogeneity has been a challenge in multiple sclerosis (MS) research. A subgroup of patients with MS shows neuropathologic features of antibody (Ab)-mediated demyelination (pattern II according to [@R1]). Observations in animal models have identified myelin oligodendrocyte glycoprotein (MOG), a molecule exposed on the myelin surface and therefore accessible to Abs, as a prime candidate antigen of demyelinating Abs,^[@R2]^ reviewed in references [@R3][@R4][@R5].

Abs against conformation-intact MOG were initially detected in children with demyelinating syndromes,^[@R6][@R7][@R9]^ more recently also in a subset of adult patients with aquaporin-4 Ab--negative neuromyelitis optica spectrum disorders (NMOSD),^[@R10][@R11][@R14]^ in adult patients with inflammatory demyelination distinct from NMOSD and MS,^[@R15]^ bilateral optic neuritis (ON),^[@R16]^ and rarely in anti-NMDA-receptor Ab--associated demyelinating syndromes.^[@R17]^ In contrast, little is known about Abs to MOG in adults with clinically definite MS according to the McDonald criteria.^[@R3],[@R4]^

Recently, we reported a patient with Abs to MOG with recurrent severe myelitis as well as brainstem involvement, who showed on biopsy a typical neuropathologic pattern II MS.^[@R18]^ This led us to hypothesize that there may exist a subgroup of patients with MS with specific clinical features who have Abs to MOG.^[@R19]^ To test this, we investigated selected patients with MS who had experienced episodes of severe ON, myelitis, or brainstem syndrome and patients with biopsy-proven CNS inflammatory demyelinating disease including MS type II pathology for Abs to MOG. In the selected MS patient cohort, we identified 5 patients who had serum Abs to MOG and assessed their anti-MOG reactivity longitudinally.

METHODS {#s1}
=======

Patients. {#s1-1}
---------

Three groups of patients with MS were investigated ([table 1](#T1){ref-type="table"}). Group 1 consisted of 104 selected patients from our outpatient clinic with a definite diagnosis of MS according to the McDonald criteria.^[@R20]^ Clinical selection criteria were as follows: relapses with severe or recurrent myelitis and/or one or more episodes of severe (visual acuity \<0.5) ON, and/or brainstem syndrome. Two neurologists (T.K. and L.A.G.) independently assessed the clinical inclusion criteria for each patient. All patients had to be negative for Abs to aquaporin-4. Group 2 consisted of 55 age- and sex-matched, otherwise unselected patients with MS. Group 3 consisted of 22 patients with biopsy-proven CNS inflammatory demyelinating disease. Four of them had MS type I pathology, 4 had MS type II pathology, 3 had MS type III pathology, while in 11 patients, MS-type classification was not possible ([table 1](#T1){ref-type="table"}). Brain biopsy was performed because of tumefactive lesions on cerebral MRI (cMRI) to rule out a tumor, and serum was taken close to this acute episode. None of the serum samples had been pretested for Abs to MOG before stratification.

###### 

Clinical characteristics of patient groups 1--3

![](NEURIMMINFL2016009266TT1)

Clinical characteristics including age, disease course, disease duration, Expanded Disability Status Scale score, MS Severity Score,^[@R21]^ first clinical manifestation, number of relapses, relapses with severe myelitis, severe ON or brainstem syndrome, MRI features, presence of oligoclonal bands (OCBs) in the CSF, presence of other autoimmune diseases, disease-modifying therapies (DMTs), and response to plasma exchange in the past (if applicable) were collected retrospectively from all patients of group 1 ([tables 1 and 2](#T1 T2){ref-type="table"}). In patients with Abs to MOG, additional stored serum samples were tested for MOG Abs longitudinally and patients were invited for follow-up visits. MRI characteristics were evaluated in more detail in all MOG Ab--positive patients. Serum samples from all patients were collected during regular visits in our outpatient clinic, immediately centrifuged, and frozen at −80°C.

###### 

Detailed clinical characteristics of 5 patients with MS who had antibodies to myelin oligodendrocyte glycoprotein

![](NEURIMMINFL2016009266TT2)

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

All patients gave written informed consent. The study was approved by the local ethics committee (project 159-03).

Detection of Abs to MOG. {#s1-3}
------------------------

For detection of Abs to MOG and for epitope mapping, serum samples from all patients were analyzed by a cell-based flow cytometric assay as previously described.^[@R18],[@R22],[@R23]^ HeLa cells were transiently transfected with human full-length MOG fused C-terminally to enhanced green fluorescent protein (EGFP)-N1 (CLONTECH Laboratories, Mountain View, CA) or with EGFP alone (control cells). For the determination of anti-MOG immunoglobulin G (IgG), 50,000 unfixed live cells were incubated 24 hours after transfection with a 1:50 dilution of the serum sample for 45 minutes at 4°C. As secondary reagents, a 1:500 dilution of a biotin-SP--conjugated goat anti-human IgG (Jackson ImmunoResearch, West Grove, PA) and a 1:2,000 dilution of Alexa Fluor 647--conjugated streptavidin (Jackson ImmunoResearch) were applied. For the determination of anti-MOG reactivity, we gated on cells with a fluorescein isothiocyanate fluorescence intensity above 500 (details and picture in [@R23]) and determined their mean channel fluorescence intensity (MFI) in the allophycocyanin channel. Then we calculated the MFI ratio between MOG-EGFP--transfected cells and cells transfected with EGFP alone. Sera that scored positive for anti-MOG IgG were also analyzed for the presence of anti-MOG immunoglobulin M (IgM) using allophycocyanin-labeled anti-human IgM (clone: SA-DA4; eBioscience, San Diego, CA). Diagnosis and clinical data were unknown to the testing person. The threshold for MOG reactivity was set to the mean plus 3 SDs (MFI ratio 2.27) of 39 adult healthy controls as described before.^[@R18]^ In addition, sera that tested anti-MOG IgG--positive in cells transiently transfected with MOG-EGFP were also analyzed with a cell line stably transfected with full-length human MOG not fused to GFP, which we had used in a previous study.^[@R8]^ This assay was performed with the same secondary reagents as described above.

Human leukocytes antigen type determination. {#s1-4}
--------------------------------------------

In all MOG Ab--positive patients, human leukocytes antigen (HLA) type determination was performed by standard molecular genotyping techniques. HLA 2-digit typing of the loci HLA-A, -B, -C, -DRB1, and -DQB1 was performed using sequence-specific oligonucleotide technique.

RESULTS {#s2}
=======

Abs to MOG in adult patients with MS. {#s2-1}
-------------------------------------

Five of 104 patients with MS from group 1 had Abs to MOG ([figure 1A](#F1){ref-type="fig"}). In contrast, none of the unselected patients with MS from group 2 and none of the patients with CNS demyelinating disease who had undergone brain biopsy from group 3 had Abs to MOG ([figure 1A](#F1){ref-type="fig"}). [Figure 1A](#F1){ref-type="fig"} shows the anti-MOG response of all analyzed patients and figure e-1 at [Neurology.org/nn](10.1212/NXI.0000000000000257) shows the histograms of the flow cytometric analysis of the 5 patients with MOG Abs. The intensity of anti-MOG reactivity in these cases was similar to our previously published case with MOG Abs and MS type II pathology.^[@R18]^ These 5 patients tested positive for anti-MOG IgG (figure e-1A) but negative for anti-MOG IgM (data not shown). We could analyze the anti-MOG response longitudinally in these 5 patients with a mean observation period of 7 years ([figures 1, B and C](#F1){ref-type="fig"}; e-2). In 3 of these patients, we noted intermittent disappearance and reappearance of the anti-MOG response ([figures 1, B and C](#F1){ref-type="fig"}; e-2C). This was particularly striking in patient 2 in whom a strong anti-MOG response transiently disappeared and then reappeared 7 years later at a similar intensity ([figure 1C](#F1){ref-type="fig"}). In this patient, we observed exactly the same epitope specificity in the anti-MOG response that reappeared after 7 years ([figure 1D](#F1){ref-type="fig"}). Each of the 5 patients with Abs to MOG showed a different reactivity to our panel of MOG mutants ([figures 1D](#F1){ref-type="fig"}; e-1, B--E) indicating interindividual heterogeneity of epitope specificity. Specifically, mutations of amino acids 42, 86, and 103/104 of MOG revealed heterogeneity between different patients. Four of these 5 patients showed a higher binding to deglycosylated MOG (N31D) than to wild-type MOG ([figures 1D](#F1){ref-type="fig"}; e-1, B, D, and E). In addition to the measurements with transiently transfected cells, we used a stably transfected cell line with full-length human MOG not fused to EGFP^[@R8]^ for the 5 anti-MOG--positive patients and noted an anti-MOG response only in 2 of these 5 patients. Thus, the assay with the stably transfected cells^[@R8]^ is less sensitive than the method used in this study with a transient transfection of MOG-EGFP and gating on the cells with the highest EGFP expression.

![Antibodies to MOG in a proportion of adult patients with MS\
(A) Sera from 3 groups of patients with MS were analyzed for anti-MOG reactivity. Group 1: patients with MS with a specific clinical phenotype, namely, with severe or recurrent myelitis and/or severe (visual acuity \<0.5) or recurrent optic neuritis, and/or brainstem syndrome (n = 104). Group 2: unselected patients with MS matched for age and sex (n = 55). Group 3: biopsied patients (n = 22), 4 with MS type II pathology (empty triangles). The red line indicates the cutoff for anti-MOG positivity. Values shown for each anti-MOG IgG--positive patient represent the mean of 3 independent measurements using the first serum sample analyzed, which was 14, 16, 3, 18, and 9 years after disease onset for patients 1 through 5. (B, C) Clinical features, therapies, and longitudinal analysis of antibodies to MOG in patients 1 and 2. (D) Analysis of the epitope specificity of the MOG reactivity of the samples indicated with asterisks (\*) in C. Reactivity of the serum samples diluted 1:50 to the indicated variants of hMOG and to mMOG is shown. Values obtained with wild-type hMOG were set as 100% and the other reactivities were calculated as described.^[@R22]^ Depicted are the mean values of 3 independent experiments ± SEM. DMF = dimethyl fumarate; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; FTY = fingolimod; GLAT = glatiramer acetate; hMOG = human myelin oligodendrocyte glycoprotein; IgG = immunoglobulin G; IVIG = IV immunoglobulins; MFI = mean fluorescence intensity; mMOG = mouse myelin oligodendrocyte glycoprotein; MOG = myelin oligodendrocyte glycoprotein; MS = multiple sclerosis; NAT = natalizumab; PLEX = plasma exchange; RX = rituximab.](NEURIMMINFL2016009266FF1){#F1}

Clinical phenotype of anti-MOG--positive patients with MS. {#s2-2}
----------------------------------------------------------

Detailed clinical characteristics of anti-MOG--positive patients with MS are shown in [table 2](#T2){ref-type="table"}. All 5 patients with MS had a typical relapsing-remitting MS with several relapses over time, typical CSF findings with presence of OCBs, and MS-typical cMRI features from the beginning of the disease ([figures 2, A.a and A.b](#F2){ref-type="fig"}; e-3). In addition, patients 1--4 had recurrent and severe myelitis with evidence of severe spinal cord involvement on spinal MRI including longitudinally extensive transverse myelitis in patients 2 and 3 ([table 2](#T2){ref-type="table"}; [figure 2, A.g, B, and C](#F2){ref-type="fig"}). They also showed severe brainstem involvement on cMRI ([figure 2, A.c--A.f](#F2){ref-type="fig"}). When we compared the clinical features of the 5 anti-MOG--positive patients with MS to anti-MOG--negative patients of group 1, we noted that 4 patients with Abs to MOG had concomitant severe spinal cord and brainstem involvement, while this combination was seen in only 7 of 99 patients without Abs to MOG. A combination of all 3 specific clinical characteristics (severe/recurrent ON, severe/recurrent myelitis, and brainstem syndrome) was observed in 3 of 5 patients with Abs to MOG and in 3 of 99 patients without Abs to MOG (table e-1). Three of 5 patients with MS who had Abs to MOG carried the HLA-DRB1\*15 allele suggesting that the well-established HLA-DR2 linkage is also present within this subgroup of patients with MS; patient 1 carried an HLA-DRB1\*03 allele that has been associated with NMOSD. None of these 5 patients tested positive for anti-NMDAR Abs.

![MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein\
(A) Patient 2: cerebral MRI showing typical MS deep white matter lesions (A.a, T2w, axial plane) and partially confluent callosal lesions (A.b, FLAIR, sagittal plane). Furthermore, bilateral lesions in the periaqueductal gray (A.c, T2w, A.d: magnified view) and bilateral pontomedullary lesions were observed (A.e, T2w, A.f: magnified view). sMRI displaying LETM and segmental atrophy in the lower thoracic and lumbar spinal cord (A.g, level T8-T11). (B) Patient 1: sMRI showing multiple partially confluent lesions in the cervical cord from C1-C6 (FLAIR, sagittal) and in the thoracic cord with focal atrophy. (C) Patient 3: sMRI demonstrating LETM from C2-C5 (FLAIR, sagittal). FLAIR = fluid-attenuated inversion recovery; LETM = longitudinally extensive transverse myelitis; MS = multiple sclerosis; sMRI = spinal MRI; T2w = T2-weighted.](NEURIMMINFL2016009266FF2){#F2}

All 5 patients with MS who had MOG-specific Abs showed an active disease course as indicated by high relapse rates and therapy failure to several DMTs ([tables 2](#T2){ref-type="table"} and e-1). Severe relapses at the beginning of MS led to Expanded Disability Status Scale scores ≥4.0 in 4 patients early on. In 2 patients, natalizumab had a sustained treatment effect on clinical disease activity. Two patients stabilized with rituximab therapy. Three of the 5 patients with Abs to MOG were treated with plasma exchange for steroid-resistant exacerbations; all 3 responded favorably to this intervention.

Serum samples from MOG Ab--positive patients were not available from disease onset; however, we could analyze the anti-MOG response longitudinally in all 5 patients with a mean observation period of 7 years ([figures 1, B and C](#F1){ref-type="fig"}; e-2). The anti-MOG reactivity fluctuated over time and only partially correlated with clinical disease activity. In patients 1 and 2, anti-MOG reactivity reappeared during episodes of clinical and/or radiologic disease activity during long-term observation ([figure 1, B and C](#F1){ref-type="fig"}). Patient 3 tested positive for MOG Abs during a severe brainstem and ON relapse, but tested negative 7 and 8 years later during a phase of clinical stabilization while under natalizumab therapy (figure e-2A). Patient 4 could be tested only twice during a time interval of 2 years and showed ongoing clinical and paraclinical disease activity accompanied by positive anti-MOG reactivity at both time points (figure e-2B). In patient 5 with a stable disease course, Abs to MOG fluctuated during continuous natalizumab treatment (figure e-2C).

DISCUSSION {#s3}
==========

We identified 5 adult patients who fulfilled the McDonald criteria for MS and who tested positive for serum anti-MOG IgG. These patients with MS had clinical features seen in patients with NMOSD,^[@R19]^ namely, relapses with severe ON, myelitis, and/or brainstem syndrome. On spinal MRI, 4 of these 5 patients showed severe spinal cord involvement with multisegmental lesions as well as extensive cord atrophy including longitudinally extensive transverse myelitis in 2 patients. Otherwise, all 5 patients had typical MS lesions on cranial MRI, positive OCBs in the CSF, and a typical relapsing-remitting MS disease course. It has already been assumed that some patients with Abs to MOG represent a subgroup of opticospinal MS,^[@R24]^ a notion supported by our observation but also expanded by the fact that our patients had otherwise rather typical MS.

Because we had stored longitudinal serum samples from these patients, we could follow their anti-MOG responses for up to 9 years. Abs to MOG tended to fluctuate over time and intermittently fell below cutoff. This indicates that cross-sectional studies may underestimate the prevalence of anti-MOG IgG, arguing for repeated testing. Using our panel of MOG mutants,^[@R22]^ we mapped the epitopes of conformation-intact MOG recognized by the patients\' Abs. Interindividual comparison showed that all 5 patients recognized different epitopes of MOG, in line with the epitope heterogeneity observed in pediatric demyelination.^[@R22]^ In one patient, the anti-MOG reactivity reappeared after 7 years, and remarkably showed the same epitope specificity. This is compatible with the view that reappearance of MOG Abs after years of seronegativity reflects reactivation of previously differentiated B cells and is similar to our previously described case of MOG Ab--positive encephalomyelitis.^[@R18]^ The intensity of the anti-MOG reactivity in these 5 patients is similar to the reactivity of a previous case sharing features of NMOSD where anti-MOG reactivity was associated with activated complement at the site of active demyelination^[@R18]^ but was lower than the reactivity we have observed in some patients with typical NMOSD (supplement in [@R18]).

The presence of Abs to MOG in adult MS has been a contentious debate for more than a decade (reviewed in [@R3]). While earlier studies using cell-based assays reported a high percentage of Abs to MOG in adult patients with MS,^[@R25],[@R26]^ several studies that included childhood demyelinating disorders^[@R7],[@R8]^ or adults with NMOSD^[@R12],[@R16]^ found little or no reactivity to MOG in adult MS.^[@R12],[@R27][@R28][@R29]^ However, in most of these studies, patients with MS were not selected for a specific phenotype. Only in a very recent report, it is stated that 4 of 26 patients with MS who all tested negative for Abs to MOG had clinical features of NMOSD.^[@R15]^ In our observation, especially patients with concomitant spinal cord and brainstem involvement tested positive for Abs to MOG, indicating that such patients with MS should be screened for the presence of MOG Abs. Patients with MS who have Abs to MOG may be at higher risk of progressive disease and need escalating therapies, as indicated by high relapse rates and lack of satisfactory response to several DMTs in the past. Two patients showed a favorable response to rituximab, which is observed in MS as well as in patients with NMOSD. Two other patients stabilized with natalizumab therapy supporting the diagnosis of MS rather than NMOSD.

It is difficult to estimate the frequency of Abs to MOG in adult MS. Our present observations indicate that it may range between 5% (in a selected cohort with specific clinical features) and less than 1% in unselected MS cohorts. Furthermore, it is unknown whether and how the presence of serum Abs to MOG is related to the neuropathologically defined MS type II.^[@R1]^ Our previous observation regarding a patient with anti-MOG--associated encephalomyelitis and neuropathologic MS type II,^[@R18]^ and 2 recent cases with fulminant encephalomyelitis and Abs to MOG,^[@R30],[@R31]^ indicate that at least a subgroup of MS type II might be associated with Abs to MOG. However, our present observation that none of 22 biopsied cases, including 4 cases of MS type II, tested positive for anti-MOG Abs indicates that MS type II in itself may be heterogeneous, and is possibly associated with Abs against different antigens. This conclusion is in harmony with the recent observation that only 1 of 13 patients with an MS type II pathology have Abs to MOG.^[@R31]^ However, as discussed above, it should be noted that MOG Ab reactivity may escape detection if MOG Abs transiently fall below cutoff.

One limitation of our study is the relatively small number of anti-MOG--positive patients with MS, although it is still the largest and best-characterized cohort of anti-MOG--positive adult MS described to date. Furthermore, no serum samples were available from the time of clinical onset and thus the role of Abs to MOG in early MS is still not known. We do not know whether Abs to MOG were present from the beginning or developed later during the course of MS. Previous pediatric studies detected anti-MOG Abs at the first demyelinating event arguing for a primary event in these patients.^[@R7],[@R8]^ Recent animal experiments, however, showed that an autoimmune reaction against MOG can follow a toxic oligodendrocyte death.^[@R32]^ Thus, Abs to MOG could be primary or secondary; therefore, we propose that also adult patients with MS who have the clinical phenotype we describe here should be tested at disease onset and also later for Abs to MOG.

These Abs to conformationally intact MOG as displayed in a cell-based assay are expected to contribute to the pathogenicity in these patients, because (1) in rodent and primate models, such MOG Abs induce demyelination (reviewed in [@R5]), (2) the breached blood--brain barrier in MS allows entry of Abs, (3) sera from anti-MOG--positive patients induced damage in oligodendroglioma cells in vitro,^[@R33]^ (4) intracerebral injection of pooled anti-MOG--positive sera from patients with NMOSD induced pathology,^[@R34]^ and (5) intrathecal injection of IgG from an anti-MOG--positive patient enhanced encephalitis in rodents.^[@R35]^

Taken together, Abs to MOG can be found in a small proportion of adult MS. Especially MS patients with concomitant severe spinal cord and brainstem involvement should be tested for Abs to MOG. Our longitudinal analysis showed that anti-MOG reactivity may fluctuate over time, indicating that repeated analysis may be helpful if clinical features are compatible with anti-MOG--associated MS. It remains to be seen whether patients with MS who have Abs to MOG benefit from specific therapies and whether Abs to MOG will be a useful biomarker.

Supplementary Material
======================

###### Data Supplement

Funding information and disclosures are provided at the end of the article. Go to [Neurology.org/nn](10.1212/NXI.0000000000000257) for full disclosure forms. The Article Processing Charge was paid by Institute of Clinical Neuroimmunology, LMU-Munich.

Supplemental data at [Neurology.org/nn](10.1212/NXI.0000000000000257)

The authors thank Drs. N. Kawakami and K. Dornmair for comments on the manuscript. They also thank EUROIMMUN (Labor Dr. Stöcker, Lübeck, Germany) for anti-NMDAR Ab testing.

AUTHOR CONTRIBUTIONS
====================

M. Spadaro: acquisition, analysis and interpretation of data, manuscript writing. Dr. Gerdes, Dr. Kümpfel: study design, patient evaluation and care, acquisition and interpretation of clinical data, manuscript writing. Dr. Krumbholz: statistical analysis, patient evaluation and care, interpretation of data, manuscript writing. Dr. Ertl-Wagner: MRI data analysis and interpretation, manuscript writing. Dr. Thaler, Dr. Schuh: patient evaluation and care, interpretation of data, manuscript editing. Dr. Metz: neuropathology of biopsy cases, manuscript editing. Dr. Blaschek: patient evaluation and care, interpretation of data, manuscript editing. Dr. Dick: HLA analysis, manuscript editing. Prof. Brück: neuropathology of biopsy cases, manuscript editing. Prof. Hohlfeld: supervision of patient care, interpretation of the data, manuscript writing and editing. Prof. Meinl: study design, interpretation of data, manuscript writing and editing, fund-raising.

STUDY FUNDING
=============

This study was supported by the Deutsche Forschungsgemeinschaft (SFB-TR 128; B8, SyNergy), the Klinische Kompetenznetz Multiple Sklerose, Verein zur Therapieforschung für MS Kranke, Werner Reichenberger Stiftung, and Gemeinnützige Hertie-Stiftung.

DISCLOSURE
==========

M. Spadaro reports no disclosures. L.A. Gerdes received travel funding and/or speaker honoraria from Biogen, Bayer Schering, received research support from Gemeinnützige Hertie-Stiftung. M. Krumbholz received travel funding from Novartis, Niogen, consulted for Genzyme, received research support from Novartis. B. Ertl-Wagner served on the scientific advisory boards for Philips, Bracco, Springer Medical Publisher, received travel funding and/or speaker honoraria from Siemens, Philips, Bracco, Bayer Schering, is an associate international editor for *Journal of American College of Radiology*, is on the editorial board for *European Radiology*, received publishing royalties from Springer Medical Publisher, Thieme Medical Publisher, has consulted for Munich Medical International, Philips Healthcare, received research support from Guerbet, Eli Lilly, Bracco, Merck Serono, Novartis, Bayer Schering institutional support, Bundesministerium fuer Forschung und Technik, Deutsche Forschungsgemeinschaft, NIH, Bayerische Forschungsstiftung, spouse holds stock or stock options for Siemens Healthcare. F.S. Thaler received travel support from Novartis. E. Schuh reports no disclosures. I. Metz received travel funding and/or speaker honoraria from Biogen Idec, Bayer Healthcare, TEVA, Serono, Novartis, Genzyme, received research support from Biogen Idec, German Ministry for Education and Research. A. Blaschek served on the scientific advisory board for Novartis, received travel funding from Novartis, Merck Serono, is on the editorial board for *European Journal of Pediatric Neurology*. A. Dick reports no disclosures. W. Brück serves on the scientific advisory board for Genzyme, Novartis, Biogen, Teva, received speaker honoraria from Teva, Sanofi, Genzyme, Novartis, Merck Serono, Biogen, Bayer, is on the editorial board for *Acta Neuropathologica*, *Therapeutic Advances in Neurological Disorders*, *Multiple Sclerosis International*, *Neuropathology and Applied Neurobiology*, received research support from Teva Pharma, Novartis, Biogen, Genzyme, German Research Foundation, Tschira Foundation, served as an expert witness for Teva Pharma. R. Hohlfeld served on the scientific advisory board for Novartis, Biogen Idec, Bayer Schering, Merck Serono, Sanofi-Aventis, Teva, CSL Behring, MedDay, Actelion, received travel funding from Novartis, Biogen Idec, Bayer Schering, Merck Serono, Sanofi-Aventis, Teva, Genzyme, is on the editorial board for *Neurology*®, *Brain*, *Clinical and Experimental Immunology*, *Deutsche Medizinische Wochenschrift*, *Expert Opinion on Biological Therapy*, *Journal of Neuroimmunology*, *Multiple Sclerosis*, *Nervenarzt*, *Practical Neurology*, *Seminars in Immunopathology*, *Therapeutic Advances in Neurological Disorders*, has consulted for Novartis, Biogen Idec, Bayer Schering, Merck Serono, Sanofi-Aventis, Teva, Genzyme, MedDay, Actelion, received research support from Novartis, Biogen Idec, Bayer Schering, Teva. E. Meinl received honorarium from Roche, served on the editorial board for *Journal of Pathology*, *Clinical Experimental Immunology*, *PLoS One*, *Journal of Biological Chemistry*, received research support from Novartis, DFG, SFB TRR 128, BMBF, KKNMS. T. Kümpfel received travel funding and/or speaker honoraria from Teva, Merck Serono, Genzyme, Novartis, Biogen Idec. Go to [Neurology.org/nn](10.1212/NXI.0000000000000257) for full disclosure forms.

Ab

:   antibody

cMRI

:   cerebral MRI

DMT

:   disease-modifying therapy

EGFP

:   enhanced green fluorescent protein

HLA

:   human leucocyte antigen

IgG

:   immunoglobulin G

IgM

:   immunoglobulin M

MFI

:   mean fluorescence intensity

MOG

:   myelin oligodendrocyte glycoprotein

MS

:   multiple sclerosis

NMOSD

:   neuromyelitis optica spectrum disorders

OCBs

:   oligoclonal bands

ON

:   optic neuritis

[^1]: These authors contributed equally to this work.
